Lunit (KRX:328130.KQ), a leading provider of AI for cancer diagnostics and therapeutics, announced on May 23 that 12 studies featuring its AI-powered digital pathology solution will be presented at the 2025 American Society of Clinical Oncology...

From Aignostics GmbH: Strategic multi-year research collaboration to identify novel targets with strong disease links and to accelerate clinical development, further strengthening Bayer’s precision oncology development portfolio ...

While precision oncology has shown great promise, there are still barriers to its implementation, such as data fragmentation, staff shortages and time, funding, and lack of standardization Use of efficient, easy-to-use, and integrated...

Lunit and the Japan National Cancer Center Hospital East Partner in AI Pathology to Advance Precision Oncology Collaborative research with Japan's largest oncology practice shows Lunit SCOPE's potential in predicting clinical outcomes...

Today marks the beginning of a new era in the field of cancer diagnosis and precision medicine with the coming together of two leading organizations Crosscope Inc. a Silicon Valley-based leader and provider of Vendor Agnostic AI-enabled Digital...